- Conditions
- Oncology
- Interventions
- Sym013
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 33,584
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
- Interventions
- Posaconazole, ABT-199, Decitabine, Azacitidine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 13
- States / cities
- Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
- Conditions
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions
- TAS6417
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
- Conditions
- COVID-19
- Interventions
- Lenzilumab, Placebo, Remdesivir
- Biological · Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Monitored Anesthesia Care
- Interventions
- arm 1, LUSEDRA, Propofol (arm 3)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City Utah, Utah
- Conditions
- Osteoporosis
- Interventions
- Romosozumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more
- Conditions
- Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Interventions
- Tegavivint, Gemcitabine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Febrile Morbidity, Pain
- Interventions
- ketorolac, saline
- Drug
- Lead sponsor
- Ascher-Walsh, Charles, M.D.
- Individual
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumor
- Interventions
- DS-1471a
- Drug
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Sarasota, Florida • Milwaukee, Wisconsin
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- SRP-4045, Placebo
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 7 Years to 21 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
- Conditions
- Healthy, no Evidence of Disease
- Interventions
- diindolylmethane, placebo, pharmacological study, laboratory biomarker analysis, quality-of-life assessment
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 30
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
- Conditions
- Clostridium Difficile
- Interventions
- Fecal Microbiota Preparation
- Drug
- Lead sponsor
- Microbiome Health Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Naperville, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 1 more
- Conditions
- Advanced Cancer
- Interventions
- Relatlimab, Nivolumab, BMS-986205, Ipilimumab
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 5
- States / cities
- Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
- Biological · Drug
- Lead sponsor
- Stephan Grupp MD PhD
- Other
- Eligibility
- 0 Years to 29 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- MGCD0103
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Female Sexual Dysfunction
- Interventions
- Geneveve Treatment, Sham Treatment
- Device
- Lead sponsor
- Viveve Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 19
- States / cities
- La Mesa, California • Orange, California • Denver, Colorado + 16 more
- Conditions
- Healthy Lactating Women
- Interventions
- SPN-812 (600mg, QD)
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Gestational Diabetes
- Interventions
- Insulin, Metformin
- Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Nicotine Dependence
- Interventions
- Nicotine patch, ENDS, Placebo patch, Placebo ENDS
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pancreatic Cancer
- Interventions
- Gemcitabine, Opioid Growth Factor (OGF)
- Drug · Biological
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Allentown, Pennsylvania • Hershey, Pennsylvania
- Conditions
- LPL Deficiency
- Interventions
- alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil
- Drug
- Lead sponsor
- UniQure Biopharma B.V.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Arthritis, Rheumatoid
- Interventions
- GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 46
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
- Conditions
- Dengue
- Interventions
- TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 20 Years to 49 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Silver Spring, Maryland